Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y. Nakashima Y, et al. Among authors: tsuru t. Mod Rheumatol. 2010 Aug;20(4):343-52. doi: 10.1007/s10165-010-0290-x. Epub 2010 May 18. Mod Rheumatol. 2010. PMID: 20480201
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M; Iguratimod-Clinical Study Group. Ishiguro N, et al. Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26. Mod Rheumatol. 2013. PMID: 22833377 Clinical Trial.
Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y. Nakashima Y, et al. Among authors: tsuru t. Mod Rheumatol. 2013 Apr 8. doi: 10.1007/s10165-013-0878-z. Online ahead of print. Mod Rheumatol. 2013. PMID: 23563508
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K; Iguratimod-Clinical Study Group. Hara M, et al. Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7. Mod Rheumatol. 2014. PMID: 24252050 Clinical Trial.
Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y. Nakashima Y, et al. Among authors: tsuru t. Mod Rheumatol. 2014 Mar;24(2):258-64. doi: 10.3109/14397595.2013.854069. Mod Rheumatol. 2014. PMID: 24593201 Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T, Tanaka Y, Kishimoto M, Saito K, Yoshizawa S, Takasaki Y, Miyamura T, Niiro H, Morimoto S, Yamamoto J, Lledo-Garcia R, Shao J, Tatematsu S, Togo O, Koike T. Tsuru T, et al. Mod Rheumatol. 2016;26(1):87-93. doi: 10.3109/14397595.2015.1079292. Epub 2015 Oct 19. Mod Rheumatol. 2016. PMID: 26382733 Clinical Trial.
Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.
Nakashima Y, Miyahara H, Kondo M, Fukuda T, Harada H, Haraguchi A, Inoue Y, Ishinishi T, Maekawa M, Maeyama A, Nakashima M, Shono E, Suematsu E, Shimauchi T, Tsuru T, Tsukamoto H, Yoshizawa S, Yoshizawa S, Iwamoto Y. Nakashima Y, et al. Among authors: tsuru t. Mod Rheumatol. 2017 Jan;27(1):15-21. doi: 10.3109/14397595.2016.1170958. Epub 2016 May 4. Mod Rheumatol. 2017. PMID: 27142240
Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.
Nakashima Y, Kondo M, Shono E, Ishinishi T, Tsukamoto H, Kuroda K, Maeyama A, Harada H, Maekawa M, Shimauchi T, Nagamine R, Jojima H, Yoshizawa S, Tsuru T, Otsuka T, Miyahara H, Suematsu E, Wada K, Yoshizawa S, Inoue Y, Fukuda T, Ikemura S, Haraguchi A. Nakashima Y, et al. Among authors: tsuru t. Mod Rheumatol. 2020 Sep;30(5):807-815. doi: 10.1080/14397595.2019.1676369. Epub 2019 Oct 17. Mod Rheumatol. 2020. PMID: 31580188
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production.
Yamada H, Tsuru T, Otsuka T, Maekawa M, Harada H, Fukuda T, Tsukamoto H, Maeyama A, Yoshizawa S, Wada K, Nakashima Y, Shono E, Yoshizawa S, Jojima H, Kondo M. Yamada H, et al. Among authors: tsuru t. Immunol Med. 2020 Jun;43(2):87-91. doi: 10.1080/25785826.2020.1718833. Epub 2020 Jan 29. Immunol Med. 2020. PMID: 31994996 Free article.
301 results